A big win for generic drug makers at the Federal Circuit
A brand-name drug company can't sue generic drug companies for patent infringement if the generics ask the government to approve only nonpatented uses for the drug, the Federal Circuit has ruled, dismissing AstraZeneca's case against Apotex and several other generic drug companies.
